Incyte Corp.

NASDAQ:INCY   12:22:08 PM EDT
65.42
+0.84 (+1.30%)
Products, Regulatory, Earnings Announcements

Incyte Announces Results From Phase 3 Devent Study Evaluating Ruxolitinib As Treatment For Covid-19 Associated ARDS

Published: 03/18/2021 21:42 GMT
Incyte Corp. (INCY) - Incyte Announces Results From the Phase 3 Devent Study Evaluating Ruxolitinib (jakafi®) As a Treatment for Patients With Covid-19 Associated Acute Respiratory Distress Syndrome (ards) on Mechanical Ventilation.
Incyte Corp - Improvement in Mortality for Each Dose Compared to Placebo, While Trending Toward Positive, Was Not Statistically Significant.
Incyte Corp - Significant Improvement in Mortality Seen in U.S. Study Participants at Both Doses.
Incyte Corp - Devent Study Did Not Meet Its Primary Endpoint-mortality.
Revenue is expected to be $738.6 Million
Adjusted EPS is expected to be $0.58

Next Quarter Revenue Guidance is expected to be $795.48 Million
Next Quarter EPS Guidance is expected to be $0.59

More details on our Analysts Page.